Stapokibart injection for atopic dermatitis in adults
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctor independently decided you should try Stapokibart for your atopic dermatitis
- You do not have a known allergy to Stapokibart
- You are not currently enrolled in another treatment study and do not plan to be
- You do not have blood cancers (hematologic malignancies)
- If you are a woman, you are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new foam medication for adults with atopic dermatitis (a type of eczema). It aims to see if the foam is better than a placebo (a foam with no active ingredient) at treating the condition.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This study looks at how well an allergy injection called Stapokibart works for people with seasonal allergic rhinitis (hay fever). If you qualify, you'll receive the treatment as part of your normal care, and the study team will track your results.
This trial tests a new injection called Stapokibart to see if it can help people with moderate to severe bullous pemphigoid, a skin condition that causes painful blisters. The treatment aims to reduce blistering and itching.
This study tests an injectable medication called Stapokibart for teenagers with seasonal allergies (hay fever). It aims to see if the drug can reduce allergy symptoms like sneezing, runny nose, and itchy eyes.
This study is a follow-up for children who have already completed the first 18 weeks of treatment with the study medicine for atopic dermatitis (also called eczema). It tests whether the medicine continues to be safe and effective over a longer time.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.